" class="no-js "lang="en-US"> Doug Ethell - Medtech Alert
Tuesday, September 16, 2025
Doug Ethell

Doug Ethell

About Doug Ethell

Dr. Ethell’s groundbreaking research serves as the foundation for Leucadia Therapeutics’ work. A PhD in Neuroscience, he has studied Alzheimer’s disease for 20 years. He was a Human Frontiers of Science Long-term Fellow at the Max Planck Institute for Psychiatry in Germany and a Research Associate at the Scripps Research Institute in La Jolla, California. Dr. Ethell ran Alzheimer’s disease research at the La Jolla Institute for Immunology, served on the faculty at the University of California Riverside, and later founded the Molecular Neurobiology Group at the Western University of Health Sciences in Pomona, California, where he also chaired the Department of Neuroscience. He has authored more than 85 papers and presentations.

Related Story

Prominent Neurosurgeon Joins Leucadia Therapeutics as Company's Founding Global Chief Medical Officer

August 23 2022

Leucadia Therapeutics, a company working to cure Alzheimer’s disease, has hired a global chief medical […]